Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Proteome Sciences (PRM) by Steve Moore in ShareProphets
- Sell Thruvision Group (THRU) by Steve Moore in ShareProphets
- Underperform British American Tobacco (BATS) by RBC Capital
- Buy Unilever (ULVR) by DZ Bank
- Add Aviva (AV.) by Simon Watkins in The Motley Fool
- Buy BT Group (BT.A) by Simon Watkins in The Motley Fool
- Underperform Unilever (ULVR) by RBC Capital
- Hold Rio Tinto (RIO) by LBBW
- Hold Aviva (AV.) by Kepler Cheuvreux
- Hold Admiral Group (ADM) by Kepler Cheuvreux
- Reduce Legal & General Group (LGEN) by Kepler Cheuvreux
- Hold Victrex plc (VCT) by Berenberg
- Buy Applied Nutrition (APN) by Berenberg
- Outperform Moonpig Group (MOON) by RBC Capital
- Buy Ocado Group (OCDO) by Deutsche Bank
- Buy Abrdn (ABDN) by Deutsche Bank
- Buy Relx plc (REL) by Deutsche Bank
- Sell ITM Power (ITM) by Goldman Sachs
- Underweight Kingfisher (KGF) by Barclays
- Buy Barclays (BARC) by UBS
Belluscura (BELL) Share Price
Health Care Sector
NOTE: This is based on 4 open tips for Belluscura (BELL)
| Latest Bid : 0.70p | Latest Ask : 0.80p |
| High Today : 0.92p | Low Today : 0.70p |
| This Years High : 16.00p | This Years Low : 0.55p |
| Volume : 2,751,008 | MKT Cap : £1.26M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Belluscura (BELL) Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.Belluscura (BELL) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2025-04-16 08:50:00 16/04/2025 | -7.14% |
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 96.59% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -98.75% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -83.33% |
Belluscura (BELL) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 0.70p | Latest Ask : 0.80p |
| High Today : 0.92p | Low Today : 0.70p |
| This Years High : 16.00p | This Years Low : 0.55p |
| Volume : 2,751,008 | MKT Cap : £1.26M |
Belluscura Overview
Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Belluscura Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2025-04-16 08:50:00 16/04/2025 | -7.14% |
| Sell | Tom Winnifrith | Premium Only | 2024-01-02 08:10:00 02/01/2024 | 96.59% |
| Buy | Joanne Hart | Premium Only | 2022-11-12 21:50:00 12/11/2022 | -98.75% |
| Buy | Stuart Blair | Premium Only | 2021-08-02 08:55:00 02/08/2021 | -83.33% |